When it comes to lymphocytic malignancy, the application of BTK inhibitors was a milestone especially in the fields of chronic lymphoma leukemia (CLL) therapy as well as graft versus host diseases after allogeneic hematopoietic stem cell transplantation. The gene discussed is BTK; the disease is glycogen storage disease VI.